Blood clearance rates of adenovirus type 5 in mice

References

1. Alemany R., Ruan S., Kataoka M., Koch P. E., Mukhopadhyay T., Cristiano R. J., Roth J. A., Zhang W. W. 1996; Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Therapy 3:296–301
   [Google Scholar]
2. Allemann E., Brasseur N., Benrezzak O., Rousseau J., Kudrevich S. V., Boyle R. W., Leroux J. C., Gurny R., Van Lier J. E. 1995; PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours. Journal of Pharmacy and Pharmacology 47:382–387
   [Google Scholar]
3. Brunner K. T., Hurez D., McCluskey R. T., Benacerraf B. 1960; Blood clearance of P32-labeled vesicular stomatitis and Newcastle disease viruses by the reticuloendothelial system in mice. Journal of Immunology 85:99–104
   [Google Scholar]
4. Chartier C., Degryse E., Gantzer M., Dieterle A., Pavirani A., Mehtali M. 1996; Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Journal of Virology 70:4805–4810
   [Google Scholar]
5. Chillon M., Lee J. H., Fasbender A., Welsh M. J. 1998; Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Therapy 5:995–1002
   [Google Scholar]
6. Crawford-Miksza L., Schnurr D. P. 1996; Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. Journal of Virology 70:1836–1844
   [Google Scholar]
7. Davern T. J., Sevcik A. M., Bissell M. D. 1999; In vivo adenoviral vector-mediated gene delivery to non-parenchymal cells of the liver. Hepatology 30:490A
   [Google Scholar]
8. Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M., Schoemaker R., Veghel R., Houtsmuller A., Schultheiss H. P., Lamers J., Poller W. 1999; Expression of coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 6:1520–1535
   [Google Scholar]
9. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. 1994; Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Research 54:987–992
   [Google Scholar]
10. Hierholzer J. C. 1973; Further subgrouping of the human adenoviruses by differential hemagglutination. Journal of Infectious Diseases 128:541–550
    [Google Scholar]
11. Hitt M. M., Addison C. L., Graham F. L. 1997; Human adenovirus vectors for gene transfer into mammalian cells. Advances in Pharmacology 40:137–206
    [Google Scholar]
12. Horwitz M. S. 1996; Adenoviruses. In Fields Virology pp 2149–2171 Edited by Fields B. N., Knipe D. N., Howley P. M. Philadelphia: Lippincott–Raven;
    [Google Scholar]
13. Huang S., Kamata T., Takada Y., Ruggeri Z. M., Nemerow G. R. 1996; Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. Journal of Virology 70:4502–4508
    [Google Scholar]
14. Jahrling P. B., Eddy G. A. 1977; Comparisons among members of the Venezuelan encephalitis virus complex using hydroxylapatite column chromatography. American Journal of Epidemiology 106:408–417
    [Google Scholar]
15. Kaner R. J., Worgall S., Leopold P. L., Stolze E., Milano E., Hidaka C., Ramalingam R., Hackett N. R., Singh R., Bergelson J., Finberg R., Falck-Pedersen E., Crystal R. G. 1999; Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. American Journal of Respiratory Cell and Molecular Biology 20:361–370
    [Google Scholar]
16. Kirn D. H., McCormick F. 1996; Replicating viruses as selective cancer therapeutics. Molecular Medicine Today 2:519–527
    [Google Scholar]
17. Kirn A., Gut J. P., Gendrault J. L. 1982; Interaction of viruses with sinusoidal cells. Progress in Liver Diseases 7:377–392
    [Google Scholar]
18. Leopold P. L., Ferris B., Grinberg I., Worgall S., Hackett N. R., Crystal R. G. 1998; Fluorescent virions: dynamic tracking of the pathway of adenoviral gene transfer vectors in living cells. Human Gene Therapy 9:367–378
    [Google Scholar]
19. Lieber A., He C. Y., Meuse L., Schowalter D., Kirillova I., Winther B., Kay M. A. 1997; The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of Virology 71:8798–8807
    [Google Scholar]
20. Mei Y. F., Wadell G. 1995; Molecular determinants of adenovirus tropism. Current Topics in Microbiology and Immunology 199:213–228
    [Google Scholar]
21. Mittereder N., March K. L., Trapnell B. C. 1996; Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. Journal of Virology 70:7498–7509
    [Google Scholar]
22. O’Riordan C. R., Lachapelle A., Delgado C., Parkes V., Wadsworth S. C., Smith A. E., Francis G. E. 1999; PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Human Gene Therapy 10:1349–1358
    [Google Scholar]
23. Steffan A. M. 1997; Hepatic macrophages and virus. Pathologie et Biologie 45:169–183 (in French
    [Google Scholar]
24. Wolff G., Worgall S., van Rooijen N., Song W. R., Harvey B. G., Crystal R. G. 1997; Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. Journal of Virology 71:624–629
    [Google Scholar]
25. Worgall S., Wolff G., Falck-Pedersen E., Crystal R. G. 1997; Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Human Gene Therapy 8:37–44
    [Google Scholar]